Anaphylaxis is a severe, life-threatening systemic allergic reaction. Verus Pharmaceuticals, Inc., announced study results supporting the potential need for two doses of epinephrine to treat anaphylaxis. The study, “Factors Affecting the Use of Automatic Epinephrine Injectors”, was presented today as a poster session at the 2006
Twinject®, a novel epinephrine auto-injector indicated for the emergency treatment of severe allergic reactions, is the only available product approved by the FDA that contains two doses of epinephrine in a single, compact device.
.jpg)
Comment Preview